Identifying and Managing Patients with Mixed States in Bipolar Disorder

Virtual Clinic Powered by RealCME with content provided by its educational partners

Title:

Identifying and Managing Patients with Mixed States in Bipolar Disorder

Topic: Psychiatry
Relevant Terms: Binge Eating Disorder, Bipolar Disorder, Mood Disorders, Substance Use Disorder
Primary Audience: Psychiatrists
Launch Date: 05-Jan-12
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: The Bipolar Patient: From Diagnosis to Remission

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Recognize mixed symptoms in patients with bipolar disorder
  2. Describe the impact of mixed symptoms on the course of bipolar illness
  3. Develop effective treatment strategies for patients with bipolar mixed states

    Faculty

    Michael H. Allen, MD
    Director of Inpatient Psychiatry
    Colorado Psychiatric Health
    Professor of Psychiatry
    University of Colorado School of Medicine
    Denver, Colorado
    Course Viewing Requirements
    PC
    Internet Explorer (v6 or greater), or Firefox
    MAC
    Safari
     
    Estimated time to complete activity: 0.5 hours
     
    Sponsored by


    Supported by an educational grant from


    Target Audience
    This activity has been designed to meet the educational needs of psychiatrists and other mental health care providers involved in the management of patients with bipolar disorder.
     
    Program Overview
    Patients with bipolar disorder often present with concomitant depressive and manic symptoms. These mixed states represent some of the most complex clinical challenges in terms of both diagnosis and treatment. It is important that clinicians recognize when a symptomatic episode includes more than pure mania, hypomania, or depression and whether the episode is predominantly depressive or manic. Bipolar mixed states are associated with greater severity of illness as well as treatment resistance. Effective management depends on identification and assessment of symptoms associated with both poles and may require specific adjustments in pharmacotherapy.
     
    Accreditation Statement
    SciMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
     
    Credit Designation
    SciMed designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Disclosure and Resolution of Conflicts of Interest
    SciMed requires all individuals who are involved in the development or delivery of content in any of its activities to disclose financial relationships they may have with commercial interests. Should SciMed determine that any of the disclosed relationships constitutes a conflict of interest, as defined by the ACCME, SciMed will act to resolve such a conflict. When asked to report relevant financial relationships with commercial interests, faculty reported the following:

    Michael H. Allen
    , MD
    Grants/research support: Ortho-McNeil-Janssen
    Rater training: United BioSource Corporation, i3 Research
     
    Shari Fallet, DO, an employee of SciMed and a member of the planning committee for this activity, reports owning stock in Pfizer Inc. All other SciMed personnel involved in the development of content for this activity have no relevant financial relationships to report.
     
    The materials for this activity were peer reviewed by Robert M. Post, MD, and Joseph McEvoy, MD. Drs. Post and McEvoy disclosed the following financial relationships with commercial interests:

    Robert M. Post, MD
    Consultant: AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Puretech
    Speakers Bureau: AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline.
    Honorarium: Janssen-Cilag
    Joseph McEvoy, MD
    Consultant: Roche, Sunovion
    Speakers bureau: Eli Lilly and Company, Merck & Co, Inc, Sunovion
     
     
    Off-label Product Discussion
    Faculty have indicated that this activity will include no off-label discussions.
     
    Instructions for Participating in This Activity and Obtaining CME Credit
    There are no fees for participating in and receiving CME credit for this online educational activity. To obtain CME credit for participating in this activity during the period January 5, 2012 through January 4, 2013, participants must 1) read the educational objectives and disclosure statements; 2) study the educational activity; and 3) participate in the postactivity exercise. A passing grade of 20% is required before credit can be obtained; you have 3 attempts to pass. Once you have completed the educational activity and postactivity exercise, you will be directed to complete an evaluation form.
     
    Disclaimer
    The opinions or views expressed in this CME activity are those of the presenters and do not necessarily reflect the opinions or recommendations of SciMed, LLC or Bristol-Myers Squibb and Otsuka America Pharmaceuticals Inc. Participants should critically appraise the information presented and are encouraged to consult appropriate resources for information surrounding any product, device, or procedure mentioned.